Literature DB >> 23192014

IDH1 and IDH2 mutations in therapy-related myelodysplastic syndrome and acute myeloid leukemia are associated with a normal karyotype and with der(1;7)(q10;p10).

M K Westman, J Pedersen-Bjergaard, M T Andersen, M K Andersen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23192014     DOI： 10.1038/leu.2012.347

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   12.883


× No keyword cloud information.
  9 in total

1.  High frequency of RUNX1 mutation in myelodysplastic syndrome patients with whole-arm translocation of der(1;7)(q10;p10).

Authors:  T Zhang; Y Xu; J Pan; H Li; Q Wang; L Wen; D Wu; A Sun; S Chen
Journal:  Leukemia       Date:  2017-07-19       Impact factor: 11.528

2.  Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer.

Authors:  Nidal E Muvarak; Khadiza Chowdhury; Limin Xia; Carine Robert; Eun Yong Choi; Yi Cai; Marina Bellani; Ying Zou; Zeba N Singh; Vu H Duong; Tyler Rutherford; Pratik Nagaria; Søren M Bentzen; Michael M Seidman; Maria R Baer; Rena G Lapidus; Stephen B Baylin; Feyruz V Rassool
Journal:  Cancer Cell       Date:  2016-10-10       Impact factor: 31.743

3.  Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.

Authors:  Chi Young Ok; Keyur P Patel; Guillermo Garcia-Manero; Mark J Routbort; Bin Fu; Guilin Tang; Maitrayee Goswami; Rajesh Singh; Rashmi Kanagal-Shamanna; Sherry A Pierce; Ken H Young; Hagop M Kantarjian; L Jeffrey Medeiros; Rajyalakshmi Luthra; Sa A Wang
Journal:  Leuk Res       Date:  2014-12-20       Impact factor: 3.156

4.  The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment.

Authors:  Helmut Greim; Debra A Kaden; Richard A Larson; Christine M Palermo; Jerry M Rice; David Ross; Robert Snyder
Journal:  Ann N Y Acad Sci       Date:  2014-02-04       Impact factor: 5.691

Review 5.  Rare cytogenetic abnormalities in myelodysplastic syndromes.

Authors:  Ulrike Bacher; Julie Schanz; Friederike Braulke; Detlef Haase
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-05-01       Impact factor: 2.576

6.  MGMT promoter methylation as a potential prognostic marker for acute leukemia.

Authors:  Dominika Sobieszkoda; Joanna Czech; Natalia Gablo; Marta Kopanska; Jacek Tabarkiewicz; Agnieszka Kolacinska; Tadeusz Robak; Izabela Zawlik
Journal:  Arch Med Sci       Date:  2017-10-31       Impact factor: 3.318

Review 7.  Prognostic Markers of Myelodysplastic Syndromes.

Authors:  Yuliya Andreevna Veryaskina; Sergei Evgenievich Titov; Igor Borisovich Kovynev; Tatiana Ivanovna Pospelova; Igor Fyodorovich Zhimulev
Journal:  Medicina (Kaunas)       Date:  2020-07-27       Impact factor: 2.430

Review 8.  DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.

Authors:  A P Im; A R Sehgal; M P Carroll; B D Smith; A Tefferi; D E Johnson; M Boyiadzis
Journal:  Leukemia       Date:  2014-04-04       Impact factor: 12.883

Review 9.  Isocitrate Dehydrogenase Mutations in Myelodysplastic Syndromes and in Acute Myeloid Leukemias.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Cancers (Basel)       Date:  2020-08-26       Impact factor: 6.639
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.